Louis A. Gaboury
Affiliations: | Université de Montréal, Montréal, Canada |
Area:
Pathology, Animal Physiology Biology, Oncology, Cell BiologyGoogle:
"Louis Gaboury"
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Issac MSM, Yousef E, Tahir MR, et al. (2019) MCM2, MCM4, and MCM6 in Breast Cancer: Clinical Utility in Diagnosis and Prognosis. Neoplasia (New York, N.Y.). 21: 1015-1035 |
| Goyette MA, Duhamel S, Aubert L, et al. (2018) The Receptor Tyrosine Kinase AXL Is Required at Multiple Steps of the Metastatic Cascade during HER2-Positive Breast Cancer Progression. Cell Reports. 23: 1476-1490 |
| Duhamel S, Goyette MA, Thibault MP, et al. (2018) The E3 Ubiquitin Ligase HectD1 Suppresses EMT and Metastasis by Targeting the +TIP ACF7 for Degradation. Cell Reports. 22: 1016-1030 |
| Medimegh I, Ayari H, Baraudi O, et al. (2018) Abstract P5-07-12: miR-34a as a prognostic biomarker for overall survival triple negative breast cancer within Tunisian patients Cancer Research. 78 |
| Matsuda H, Campion CG, Fujiwara K, et al. (2017) HCaRG/COMMD5 inhibits ErbB receptor-driven renal cell carcinoma. Oncotarget. 8: 69559-69576 |
| Chen L, Yuan Y, Kar S, et al. (2017) PPARγ Ligand-induced Annexin A1 Expression Determines Chemotherapy Response via Deubiquitination of Death Domain Kinase RIP in Triple-negative Breast Cancers. Molecular Cancer Therapeutics |
| Williams V, Grosset AA, Zamorano Cuervo N, et al. (2017) Detection of IKKε by immunohistochemistry in primary breast cancer: association with EGFR expression and absence of lymph node metastasis. Bmc Cancer. 17: 356 |
| Yousef EM, Furrer D, Laperriere DL, et al. (2017) MCM2: An alternative to Ki-67 for measuring breast cancer cell proliferation. Modern Pathology : An Official Journal of the United States and Canadian Academy of Pathology, Inc |
| Grosset A, Poirier F, Gaboury L, et al. (2016) Galectin-7 Expression Potentiates HER-2-Positive Phenotype in Breast Cancer. Plos One. 11 |
| Grosset AA, Labrie M, Vladoiu MC, et al. (2016) Galectin signatures contribute to the heterogeneity of breast cancer and provide new prognostic information and therapeutic targets. Oncotarget. 7: 18183-18203 |